Company: BDRX
Filing Date: 2025-09-26
Form Type: F-3
Source: 0001214659-25-014255
Chunk: 30

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-26
Form: F-3
Chunk 30
---
 dividends or other
rights as a holder of our capital stock until they exercise the warrants.

| 17 |

May 2020 United Kingdom Placing Warrants

On May 22, 2020, we issued
333,333 units, with each unit comprising one new Ordinary Share and one warrant to purchase one new Ordinary Share, or a UK Warrant. The
exercise price of the UK Warrants are £6.80 per share and they expire on November 20, 2025. We also issued UK Warrants to purchase
a total of 16,400 Ordinary Shares to Turner Pope, the placing agent, in connection with the closing of such offering, on the same terms
and conditions as the other investors in the offering.

February Placement Agent Warrants

The following is a brief summary
of the February Placement Agent Warrants, and is subject in all respects to the provisions contained in the warrant, which is filed as
an exhibit to our Report on Form 6-K dated February 9, 2023.

Exercisability.The
February Placement Agent Warrants are exercisable and expire three years from the initial exercise date. The holder shall deliver the
aggregate exercise price for the Depositary Shares specified in the exercise notice within two trading days following the date of exercise
(subject to the ‘cashless exercise’ arrangements described below).

Cashless Exercise.The
February Placement Agent Warrants may only be exercised on a cashless basis if, following a date that is six months from the original
issuance date, at the time of exercise, there is no effective registration statement registering with a current prospectus available for
resale of the Depositary Shares underlying the February Placement Agent Warrants.

Exercise Price.The
exercise price of a portion of the February Placement Agent Warrants is $58,000.00 per Depositary Share, respectively, each subject to
the ‘cashless exercise’ arrangements described above and to adjustment as described herein.

Beneficial Ownership Limitation.A holder shall have no right to exercise any portion of a February Placement Agent Warrant, to the extent that, after giving effect
to such exercise, such holder, together with such holder’s affiliates, and any persons acting as a group together with such holder
or any such affiliate, would beneficially own in excess of 4.99% of the number of Ordinary Shares outstanding immediately after giving
effect to the issuance of the Ordinary Shares underlying the Depositary Shares upon such exercise. The holder of such warrant, upon notice
to